Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Prospective Phase II Clinical Study of Tislelizumab in Combination With Chemotherapy for the Perioperative Treatment of Resectable Locally Advanced Gastric and Gastroesophageal Junction Adenocarcinoma

NCT06374901 is registered in ClinicalTrials.gov with Xiangdong Cheng as lead sponsor.

NCT NCT06374901
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06374901 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Prospective Phase II Clinical Study of Tislelizumab in Combination With Chemotherapy for the Perioperative Treatment of Resectable Locally Advanced Gastric and Gastroesophageal Junction Adenocarcinoma
Lead sponsor
Xiangdong Cheng
Phase
Phase 2
Overall status
Not yet recruiting
Start date
April 25, 2024
Completion date
March 31, 2028
Enrollment
134 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

gastric cancer